Login
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc.

tvarditherapeutics.com

What Do They Do?

Develops oral small-molecule therapies that target a cell-signaling protein for people with inflammatory and proliferative diseases.

How Are They Changing?

From itch treatments to targeted therapies The older report centers on an injection and oral treatment for chronic itch; the latest centers on oral inhibitors of a signaling protein for inflammatory and proliferative diseases.

Revenue over time
Collaborative revenue Commercial supply revenue Clinical compound revenue Other revenue (non-cash) License and Milestone Fees Royalty revenue
$200M$100M$0

Who Do They Compete With?

Competes with Moleculin Biotech, Purple Biotech, and Scopus BioPharma

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support